Halobetasol/tazarotene: Difference between revisions
Content deleted Content added
Creating article Halobetasol/tazarotene |
(No difference)
|
Revision as of 10:29, 16 January 2024
| Combination of | |
|---|---|
| Ulobetasol propionate | Corticosteroid |
| Tazarotene | Retinoid |
| Clinical data | |
| Trade names | Duobrii |
| AHFS/Drugs.com | Multum Consumer Information |
| Routes of administration | Topical |
| Legal status | |
| Legal status |
|
Halobetasol/tazarotene (Duobrii) is a topical combination drug containing a corticosteroid and a retinoid. It combines 0.01% halobetasol propionate and 0.045% tazarotene in a lotion formulation.[1][2][3] It was approved as a prescription drug for treating plaque psoriasis in adults by the U.S. Food and Drug Administration in April 2019.[2][3][4]
References
- ^ "DUOBRII- halobetasol propionate and tazarotene lotion". DailyMed. 1 January 2020. Retrieved 15 January 2024.
- ^ a b Reddy V, Myers B, Yang EJ, Bhutani T (2020). "Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults". Clinical, Cosmetic and Investigational Dermatology. 13: 391–398. doi:10.2147/CCID.S252426. PMC 7295208. PMID 32606876.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R (June 2021). "Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology". The Journal of Dermatological Treatment. 32 (4): 391–398. doi:10.1080/09546634.2019.1668907. PMID 31522563.
- ^ Duffy, Steve (26 April 2019). "FDA Approves Unique Combination Topical Therapy for Plaque Psoriasis". MPR. Retrieved 16 January 2024.
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |